Three Routes to One Axis

The short version

This page lines up CJC-1295/Ipamorelin, sermorelin, and tesamorelin on the dimensions that matter most when reading growth-hormone-axis peptide research: mechanism, most-studied application, evidence base, administration studied, regulatory status, and the single most important caution for each. All three are studied as ways to raise the body's own growth-hormone signal rather than replace GH directly — but they differ sharply in how well-tested that idea actually is. Tesamorelin has the deepest randomized-trial base and a current FDA approval, for one narrow indication. Sermorelin has real but older regulatory history and a mix of small modern trials and editorial disagreement. CJC-1295/Ipamorelin has solid pharmacology for each half and no controlled trial of the combination itself. None of this is medical advice, and no dose is recommended here.

The comparison matrix

Peptide class

The three compounds take different structural approaches to the same target. CJC-1295 is a modified GHRH(1-29) fragment, most often paired with ipamorelin, a selective pentapeptide agonist at the ghrelin receptor GHS-R1a — two molecules acting through two separate receptors on the same pituitary cell ^[5]. Sermorelin is unmodified in sequence: it is simply the natural 1-29 fragment of GHRH, the shortest piece of the hormone that retains full receptor activity. Tesamorelin keeps the complete 44-residue GHRH sequence but adds a single N-terminal modification — a trans-3-hexenoic acid group — that blocks the enzyme (DPP-IV) that would otherwise rapidly break it down, extending its effective duration relative to the unmodified hormone. All three ultimately converge on the same GHRH receptor pathway, with ipamorelin adding a second, ghrelin-receptor route.

Most-studied application

Tesamorelin's trial program is the narrowest and deepest: essentially all of its randomized-trial evidence comes from HIV-associated lipodystrophy, where it reduces visceral and hepatic fat with a consistent, statistically significant effect size across multiple trials ^[1][14][16]. Sermorelin's trial history is broader but thinner in modern data: its strongest evidence is decades-old pediatric growth-deficiency trials ^[10], with smaller, more recent studies and editorials debating adult uses like cognition and body composition ^[7][8][9]. CJC-1295/Ipamorelin has no dedicated trial program of its own; what is studied is each half separately — CJC-1295's GH/IGF-1 pharmacokinetics ^[3][4] and ipamorelin's receptor selectivity — plus one cell-based study of the two receptors working together ^[5].

Evidence base

This is where the three genuinely separate. Tesamorelin has the deepest evidence: a 2026 meta-analysis pooling five RCTs ^[1], a dedicated pivotal trial ^[14], a long-term 52-week program ^[16], and a formal drug-safety monograph ^[13] — the standard expected of an approved prescription medicine. Sermorelin's evidence is real but split across two different eras: rigorous but decades-old pediatric trials ^[10][11][12], and a smaller, more contested modern literature, including a widely cited editorial arguing anti-aging use is 'not yet ready for prime time' ^[8] alongside one arguing for sermorelin's physiologic advantages ^[9]. CJC-1295/Ipamorelin's evidence base is the thinnest as an actual combination: solid single-agent human and rodent pharmacology ^[3][4], but no controlled trial of the fixed blend, and no long-term human safety data for the combination itself.

Administration studied

All three are studied and used as subcutaneous injections. CJC-1295's DAC form is typically dosed far less frequently than ipamorelin because of its multi-day albumin-bound half-life, while ipamorelin itself clears within hours — a mismatch in timing that is part of why the fixed combination's actual exposure profile is not well characterized ^[3]. Sermorelin and tesamorelin are both dosed once daily by subcutaneous injection in their respective trial programs ^[10][14]; tesamorelin is the only one with an FDA-specified dosing regimen as part of an approved product label.

Regulatory and approval status

Tesamorelin is the only compound here with a current FDA approval — specifically for reducing excess abdominal fat in adults with HIV-associated lipodystrophy ^[13]. Sermorelin was FDA-approved for pediatric growth-hormone deficiency under a branded formulation that was withdrawn from the US market in 2008 for commercial, not safety, reasons; it is treated today as a long-standing Category 1 bulk substance under FDA's interim compounding policy. Neither CJC-1295 nor ipamorelin has ever held FDA approval for any human indication; both are sold only as research chemicals, and their compounding status has shifted repeatedly — added to and then removed from an interim restricted-substances category between 2023 and 2024. All three GHRH-pathway compounds are prohibited in sport under anti-doping rules.

Key caution

Each compound carries a defining caveat. For CJC-1295/Ipamorelin it is that the fixed combination has never been tested as a blend — its two halves have mismatched pharmacokinetics, and the actual GH exposure any given protocol produces is uncharacterized ^[3][4]. For sermorelin it is that its popular modern anti-aging and wellness applications outpace the trial evidence, with a major editorial concluding GH-secretagogue use for aging is 'not yet ready for prime time' ^[8]. For tesamorelin it is that its real regulatory rigor comes with real narrowness: the approval covers one population and one condition, its benefit reaccumulates within weeks of stopping treatment, and long-term oncologic safety beyond the trial window remains an open question ^[16]. Reading the three together, the pattern is consistent: the compound with the deepest trial evidence also has the narrowest studied population, and the compounds studied more broadly in research-use communities carry the least rigorous trial support.